Dr Martin Main has worked in the pharmaceutical industry for 25 years, at Merck, GlaxoSmithKline and AstraZeneca. Martin has extensive expertise in early-stage drug discovery, most recently leading the Discovery Biology UK department at AstraZeneca which had the remit of bioreagent generation and assay development for Oncology and Neuroscience projects.
In his current role at MDC, Martin’s group is advancing a range of drug discovery technology platforms to support collaborative projects in the areas of cellular target engagement, biomarkers, cell model analysis and drug distribution. An ion channel electrophysiologist by training, Martin holds a PhD in Cardiac Physiology from St George’s Hospital, University of London.
